Chiesi Farmaceutici
Chiesi is a global biopharmaceutical group committed to research and development of innovative therapeutic solutions in respiratory health, rare diseases, and specialized care. As a Benefit Corporation and B Corp certified since 2019, Chiesi emphasizes sustainability, social impact, and environmental responsibility, aiming for net zero emissions by 2035. With over 85 years of experience, the company operates in 31 countries with more than 6,500 employees, and invests heavily in research, innovation, and sustainable practices.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Laryngeal mask airway device and method for administering a medicament through a laryngeal mask airway device
US-12214129-B2
View DetailsPharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
US-11844860-B2
View Details
Laryngeal mask airway device and method for administering a medicament through a laryngeal mask airway device
US-12214129-B2
View DetailsPharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
US-11844860-B2
View DetailsProducts
Formoterol fumarate inhalation product
Inhaled bronchodilator formulation using formoterol fumarate; the product page references national prescribing information and regulatory summaries.
Inhaled tobramycin formulation
Inhaled antibiotic formulation using tobramycin for respiratory indications; product page links to regulatory summaries.
Pulmonary surfactant product (neonatology)
Exogenous pulmonary surfactant therapy used in neonatal respiratory distress management; product and clinical information are available via neonatal care pages.
Bronchitol (inhaled therapy product)
Product page referencing the national product monograph for up-to-date prescribing information; site advises contacting a healthcare professional for medical questions.
Foster 100/6 microgrammi per erogazione soluzione pressurizzata per inalazione
Soluzione pressurizzata per inalazione contenente beclometasone dipropionato e formoterolo fumarato diidrato per il trattamento regolare dell'asma e della BPCO.
Formoterol fumarate inhalation product
Inhaled bronchodilator formulation using formoterol fumarate; the product page references national prescribing information and regulatory summaries.
Inhaled tobramycin formulation
Inhaled antibiotic formulation using tobramycin for respiratory indications; product page links to regulatory summaries.
Pulmonary surfactant product (neonatology)
Exogenous pulmonary surfactant therapy used in neonatal respiratory distress management; product and clinical information are available via neonatal care pages.
Bronchitol (inhaled therapy product)
Product page referencing the national product monograph for up-to-date prescribing information; site advises contacting a healthcare professional for medical questions.
Foster 100/6 microgrammi per erogazione soluzione pressurizzata per inalazione
Soluzione pressurizzata per inalazione contenente beclometasone dipropionato e formoterolo fumarato diidrato per il trattamento regolare dell'asma e della BPCO.
Services
Adverse-event intake and regulatory reporting channel for suspected drug reactions.
Provision of regulated product and therapeutic information for clinicians and patients through controlled channels.
End-to-end clinical study services including protocol development, multi-phase trial execution, data transparency and decentralized trial components.
Integrated development and GMP manufacturing services for biologics, covering cell cultivation, upstream processing (250–2000 L), downstream processing, sterile fill–finish, packaging and small‑batch production for clinical and niche indications.
Structured partnering offerings for co-development, licensing and open-innovation collaborations, including digital-health partnerships.
Commercial and market access capabilities across multiple countries supported by a network of international affiliates.
Adverse-event intake and regulatory reporting channel for suspected drug reactions.
Provision of regulated product and therapeutic information for clinicians and patients through controlled channels.
End-to-end clinical study services including protocol development, multi-phase trial execution, data transparency and decentralized trial components.
Integrated development and GMP manufacturing services for biologics, covering cell cultivation, upstream processing (250–2000 L), downstream processing, sterile fill–finish, packaging and small‑batch production for clinical and niche indications.
Structured partnering offerings for co-development, licensing and open-innovation collaborations, including digital-health partnerships.
Commercial and market access capabilities across multiple countries supported by a network of international affiliates.
Expertise Areas
- Clinical trial management and decentralized trials
- Biologics discovery, development and translational R&D
- GMP biomanufacturing with downstream fill–finish and packaging
- Respiratory therapeutics and inhalation drug/device engineering
Key Technologies
- Monoclonal antibody and recombinant protein development
- Upstream bioprocessing (250–2000 L scale)
- Flexible small-batch biologics manufacturing
- Sterile fill–finish and packaging processes
News & Updates
Chiesi invests 430 million euros to establish a new biologics and inhalers manufacturing site in Nerviano, Milan, by 2030.
The Science Based Targets initiative (SBTi) approves Chiesi’s short and long-term emission reduction targets based on scientific data.
Chiesi appoints Roch Doliveux, Paolo Pucci, and Daphne Quimi as new independent directors to support growth and internationalization.
Chiesi promotes sustainability and inclusivity through an updated Code of Interdependence.
Key data for 2024 include €829 million invested in R&D, inauguration of Parma Biotech Center, and initiatives for Health Equity.
A strategic investment of €430 million to expand manufacturing capacity for biologics and inhalers.
Chiesi invests 430 million euros to establish a new biologics and inhalers manufacturing site in Nerviano, Milan, by 2030.
The Science Based Targets initiative (SBTi) approves Chiesi’s short and long-term emission reduction targets based on scientific data.
Chiesi appoints Roch Doliveux, Paolo Pucci, and Daphne Quimi as new independent directors to support growth and internationalization.
Chiesi promotes sustainability and inclusivity through an updated Code of Interdependence.
Key data for 2024 include €829 million invested in R&D, inauguration of Parma Biotech Center, and initiatives for Health Equity.
A strategic investment of €430 million to expand manufacturing capacity for biologics and inhalers.